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Recent research suggests an involvement of hippocampal neurogenesis in behavioral effects
of antidepressants. However, the precise mechanisms through which newborn granule
neurons might influence the antidepressant response remain elusive. Here, we demonstrate
that unpredictable chronic mild stress in mice not only reduces hippocampal neurogenesis,
but also dampens the relationship between hippocampus and the main stress hormone
system, the hypothalamo-pituitary-adrenal (HPA) axis. Moreover, this relationship is restored
by treatment with the antidepressant fluoxetine, in a neurogenesis-dependent manner.
Specifically, chronic stress severely impairs HPA axis activity, the ability of hippocampus to
modulate downstream brain areas involved in the stress response, the sensitivity of the
hippocampal granule cell network to novelty/glucocorticoid effects and the hippocampus-
dependent negative feedback of the HPA axis. Remarkably, we revealed that, although ablation
of hippocampal neurogenesis alone does not impair HPA axis activity, the ability of fluoxetine
to restore hippocampal regulation of the HPA axis under chronic stress conditions, occurs
only in the presence of an intact neurogenic niche. These findings provide a mechanistic
framework for understanding how adult-generated new neurons influence the response to
antidepressants. We suggest that newly generated neurons may facilitate stress integration
and that, during chronic stress or depression, enhancing neurogenesis enables a
dysfunctional hippocampus to restore the central control on stress response systems, then
allowing recovery.
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Introduction
In mammals, the hippocampus continues to generate
new neurons in the dentate gyrus (DG) throughout
adult life.
1,2 Efforts directed at understanding the
function of adult-generated neurons in the hippocam-
pus have focused primarily on their role in cognitive
processes such as contextual and spatial memory.
There is also evidence linking adult neurogenesis to
chronic stress, affective disorders and the response
to antidepressant treatment.
3–8 Indeed, stress, a major
etiological factor for anxiety/depressive disorders,
decreases the production and the survival of the
new hippocampal neurons,
9,10 whereas treatments
with antidepressants increase them
4 and blocking
hippocampal neurogenesis prevents the behavioral
effects of antidepressants in several paradigms in
rodents.
3,11–15 However, although there has been pro-
gress in elucidating the mechanisms through which
stress reduces neurogenesis, little is known about
either the function of these new neurons in triggering
stress-related disorders or in the mechanisms through
which they could exert some antidepressant effects.
The hippocampal formation is able to influence the
activity of several cortical and subcortical structures
involved in endocrine, motor, affective and cognitive
functions.
16–18 In addition to its role in strictly
mnemonic processes, the hippocampus is therefore
well positioned to modulate motivational behaviors,
emotional states and stress responses. Particularly,
the hippocampus is a regulator of the main neuroen-
docrine stress system, the hypothalamo-pituitary-
adrenal (HPA) axis.
19,20 It can modulate the activity
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www.nature.com/mpof the paraventricular nucleus (PVN) of the hypothala-
mus (starter of HPA axis) through two- or three-neuron
circuits. Indeed, hippocampal glutamatergic outputs
project toward PVN-connected GABAergic neuron
populations of stress-integrative subcortical regions
such as lateral septum, anteromedial and posteromedial
bed nucleus of stria terminalis (amBST and pmBST),
medial and ventrolateral preoptic areas, dorsomedial
and lateral hypothalamic nuclei (DMH and LH).
21,22
Affective disorders have been frequently associated
with abnormalities in HPA axis activity,
23–25 including
glucocorticoid hypersecretion and alterations of its
negative feedback.
26,27 These changes are probably
important as it has been shown that the normalization
of HPA axis activity parallels remission and reduces
the risk of relapse in depressed patients with HPA
axis abnormalities.
28–31
The DG is exquisitely sensitive to glucocorticoid
levels and may be damaged under conditions of high
glucocorticoid levels and chronic stress.
15,32,33 Within
this framework, we hypothesized that the pro-neuro-
genic effect of the antidepressant fluoxetine (a
selective serotonin reuptake inhibitor—SSRI) pro-
vides a fresh source of DG granule neurons highly
responsive to environmental cues. As such, they are
well positioned to initiate the improvement of
hippocampal function in stress integration and
perhaps, as a result, contribute to the antidepressant
response when stress systems have been disturbed.
For this purpose, we exposed mice with inhibited
hippocampal neurogenesis to the unpredictable
chronic mild stress (UCMS), an informative model
to study stress-related disorders in animals,
34,35 as it
mimics the role of socio-environmental stressors in
precipitating anxiety/depressive disorders, induces a
syndrome reminiscent of the human neuropathology
and reproduces the timeframe of the therapeutic
response to antidepressants.
33,34,36 Here, we found
that chronic stress exposure induces severe abnorm-
alities in the hippocampus-dependent regulation of
stress systems and that antidepressant treatment with
fluoxetine reverses such effects through a neurogen-
esis-dependent mechanism.
Materials and methods
A brief description of the materials and methods is
presented in this section. For a full and detailed descri-
ption, please refer to the Supplementary Information.
Animals
Male BALB/c mice were purchased from Taconic
(Germantown, NY, USA) or from Centre d’Elevage
Janvier (Le Genest Saint Isle, France) and were aged
between 3 and 4 months at the time of the beginning
of the UCMS exposure.
UCMS
The stress regimen used was previously described
33
and is a variant of the chronic mild stress procedures
described by Willner in rats.
34 UCMS mice were
repeatedly subjected to various socio-environmental
stressors according to an unpredictable schedule for
a total period of 6–8 weeks. From the third week of
UCMS onward, mice were administered intraperito-
neal (ip), once a day, with either vehicle, fluoxetine
(20mgkg
 1 per day) or SSR125543 (20mgkg
 1 per
day). Treatment was always maintained until the end
of the experiments. Body weight and coat state were
assessed weekly, as markers of the progression of the
UCMS-evoked syndrome.
33,37
Cookie test
This test required a device containing three
aligned compartments with the same dimension
(20 20 20cm). Only the colors of the walls and the
floor were different between the compartments (Figure
2a). Mice were first familiarized with a chocolate
cookie (Pepito, Lu, France) 4.5 weeks before the first
testing. One hour before testing, the regular food was
removed from the cage lid. At the time of testing, a
small amount (2±1g) of chocolate cookie (or regular
food in a control experiment) was placed at the center
of the black compartment. The mouse was initially
placed in the white compartment of the apparatus.
Each session of the test lasted five minutes. The cookie
consumption (# bites) was recorded within the 5min
test period. Four sessions of testing were performed
within 10 days (inter-test interval: 2 days).
X-ray irradiation procedure
Five weeks before UCMS, subsets of experimental
animals were exposed to three targeted X-irradiations
specifically above the hippocampus sparing the major
part of the brain according to the procedure pre-
viously described.
3,11
Immunohistochemistry
Immunohistochemistry for subgranular zone (SGZ)
proliferation was performed as previously described.
11
Rat anti-BrdU antibody (1:500, Oxford Biotechnology,
Oxfordshire, UK) was used as primary antibody
followed by rabbit anti-rat biotinylated antibody
(1:200, Vector Laboratories, Burlingame, CA, USA).
To label Fos, immunohistochemistry was performed
with a rabbit anti-Fos antibody (1:5000, PC38, Calbio-
chem, San Diego, CA, USA) followed by a donkey anti-
rabbit biotinylated antibody (1:500, Jackson Immuno-
research Laboratories, West Grove, PA, USA). The
staining was amplified with an avidin-biotin complex
(Elite ABC kit, Vector Laboratories) and visualized
with DAB (Sigma-Aldrich, St Louis, MO, USA).
For immunohistochemistry based on fluorescence
labeling, the different primary antibodies used were as
follows: mouse anti-NeuN monoclonal antibody (1:1000,
Chemicon International, Billerica, MA, USA), rat anti-
BrdU monoclonal antibody (1:500 Oxford Biotechnol-
ogy) and a rabbit anti-Fos monoclonal antibody (1:1000
Oxford Biotechnology); the secondary antibodies used
were as follows: Alexa-488nm anti-mouse, Alexa-
546nm anti-rabbit and Alexa-633nm anti-rat antibodies
(1:200, Molecular Probe, Eugene, OR, USA).
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When staining was visualized with DAB, the number
of positive cells was counted using  20 and  40
objective lens with a conventional light microscope.
For Fos-labeled cell counting of subcortical regions,
the nomenclature and nuclei boundaries used were
those defined by Paxinos and Franklin’s mouse brain
atlas.
38 Fosþ cells within each region were counted
bilaterally in consecutive sections starting from bregma
0.62 to bregma  1.58. For each animal and region, the
same number of sections was used and the volume of
each area was controlled. Regions included and
corresponding coordinates were as follows: lateral
septum (bregma (0.62–0.14)), amBST (0.62–0.02),
pmBST ( 0.10 to –0.34), anteroventral BST (0.62–
0.02), ventrolateral preoptic area (0.26 to  0.10),
medial preoptic area (0.14 to  0.46), DMH ( 1.34 to
 1.58), LH ( 0.34 to  0.70) and PVN ( 0.58 to  1.22).
When staining was visualized with fluorochrome-
labeled secondary antibodies, the number of positive
cells was counted using a  40 objective lens with
a confocal or an epifluorescence microscope. Eight
sections (16 hippocampus) along the rostro-caudal
extent of the hippocampus were examined; Bbregma:
 1.46,  1.82,  2.18,  2.54,  2.80,  3.08,  3.28,
 3.52.
38 We also counted the number of NeuNþ/
Fosþ cells in the inner part of the GCL containing
the SGZ (the two deepest rows of the GCL plus cells
touching the last row at the interface with the
hilus).
39,40 Indeed, granule cells are produced
throughout an outside-in gradient in the GCL, which
results in a high proportion of young newborn
neurons in the deepest rows bordering the hilus.
41–44
Quantification of corticosterone levels
Fecal samples were analyzed for immunoreactive
corticosterone metabolites using a 5a-pregnane-
3b,11b,21-triol-20-one enzyme-immunoassay as pre-
viously described.
45 Details regarding development,
biochemical characteristics and physiological valida-
tion of this assay have previously been described.
46,47
Plasma corticosterone levels was analyzed using a
125I-labeled corticosterone double-antibody radioim-
munoassay kit (MP Biomedicals, Solon, OH, USA)
according to the manufacturer’s protocol.
Dexamethasone (DEX) administration procedures
DEX suppression test: mice were i.p. injected with
either DEX-P (0.1mgkg
 1, five mice per group) or
saline (0.9% NaCl, five mice per group). All fecalthe
boli that were voided between 8 and 10h after the
injection were collected to measure the level of fecal
corticosterone metabolites.
Sensitivity of granule cells to novelty and gluco-
corticoid effects: mice were i.p. injected with either
DEX-P (0.1mgkg
 1, five mice per group) or saline
(0.9% NaCl, five mice per group). Thirty minutes
later, mice were placed in a circular open-field
(diameter 35cm) for 5min. Then, 90min later
(120min after injection), mice were anesthetized with
ketamine/xylazine (120 and 10mgkg
 1, respectively),
transcardially perfused and their brains were
collected for immunohistochemistry.
Intrahippocampal DEX infusion: the infusion pro-
cedure was derived from the method previously
described.
20 Mice were stereotaxically and bilaterally
implanted with guide cannulas (6mm long, 0.6mm
outer diameter, 0.36mm inner diameter). The follow-
ing coordinates were used for the guide cannula
implantation: bregma= 3.08, lateral=±2.3,
vertical= 1.4.
38 After 1-week recovery period from
the surgery, infusion cannulas (7mm long, 0.3mm
outer diameter, 0.17mm inner diameter) were placed
and extended 1mm below the guide cannulas. The
animals received bilateral infusions during 1.5min
of either vehicle (0.9% NaCl/0.2% ethanol) or DEX
(50ng in 0.6ml). In one experiment, the brain was
collected 2h following the infusion to assess DEX-
induced Fos changes in downstream brain structures
and the PVN (Figure 3). In another experiment, the
animals were killed by CO2 asphyxiation 4h follow-
ing infusion and trunk blood was collected to
measure plasma corticosterone levels (Figure 6).
Statistics
Considering that relatively small sample sizes were
used and that assumptions for parametric statistics
could not be ensured (normality and homoscedasti-
city), data were analyzed using the non-parametric
Kruskal–Wallis ‘analysis of variance by ranks’ H-test.
Significant effects (that is, P<0.05) were followed-up
with post-hoc tests (Holm-Bonferroni method) when
appropriate. P-values that are indicated in the
‘Results’ section always derived from the between-
groups comparisons using the Kruskal–Wallis H-test,
whereas P-values resulting from post-hoc compari-
sons are indicated in the figures.
Results
Hippocampal neurogenesis is required for chronic
stress reversal by fluoxetine
We first assessed the involvement of hippocampal
neurogenesis in the emergence and the recovery
of behavioral and physical changes in the UCMS.
For this purpose, mice were initially exposed to X-
irradiations 5 weeks before UCMS procedure to ablate
cell proliferation in the SGZ of the DG without
affecting other neurogenic niches (Figure 1a).
3,11 Mice
were then subjected to a 6- to 8-week UCMS
procedure or maintained under non-stressful condi-
tions (control mice). Two weeks after initiating
UCMS, mice were daily treated with either fluoxetine
(20mgkg
 1 per day, ip) or a vehicle solution (NaCl
0.9%, ip). X-irradiation induced a strong depletion of
SGZ cell proliferation (B92%, Figure 1b) indepen-
dently of the environment (control/UCMS) or the
treatment (vehicle/fluoxetine). UCMS exposure re-
sulted in significant decreases of SGZ cell prolifera-
tion (B27%, Figure 1b) and 4-week-old newborn
neurons (B34%, Supplementary Figure S1); these effects
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proliferation: P<0.0001; neurogenesis, P=0.0082).
Considering that anhedonia is one of the major
symptoms of depression, we developed a behavioral
paradigm based on the motivation for consuming a
palatable stimulus (a chocolate cookie): the Cookie
test. This test is based on the conflict between the
drive for the stimulus and the neophobic behavior of
the mouse. A reduction of the cookie consumption
may therefore be interpreted as anhedonia, a habitua-
tion deficit or a combination of both effects. We found
that session repetition resulted in a progressive
increase of the cookie consumption in control mice
(session 1, P=0.8149; session 2, P=0.1387; session 3,
P=0.0013; session 4, P=0.0001; Figure 2b). UCMS
exposure suppressed the consumption increase, an
effect, which was reversed by fluoxetine treatment.
Interestingly, although irradiated mice did not display
any behavioral alterations in control or UCMS condi-
tions, they were insensitive to the fluoxetine reversal.
As a control experiment, the substitution of the
cookie by a regular food pellet produced a quasi-null
consumption during the four sessions for all the
groups (data not shown), underlining the importance
of the ‘hedonic’ feature of the stimulus. Our results
indicate that the ablation of hippocampal neurogen-
esis on its own has no effect in the Cookie test but
prevents the fluoxetine reversal in UCMS mice.
Strikingly, similar results were also obtained when
examining body weight change (another main symp-
tom in major depression) and the coat state (Supple-
mentary Figures S2a,b).
However, we found that ‘antidepressant-like’
effects can be obtained even in irradiated mice
when using non-monoaminergic compounds such as
the corticotropin-releasing factor 1 receptor (CRF1)
antagonist SSR125543. In a protocol similar to the
previous experiment, SSR125543 (20mgkg
 1 per day,
ip) also reversed neurogenesis reduction induced by
UCMS (P=0.018; Supplementary Figure S1c). This
compound counteracted UCMS effects in the Cookie
test (session 1, P=0.9998; session 2, P=0.8644;
session 3, P=0.0714; session 4, P=0.0108; Figure
2c), on body weight and coat state (Supplementary
Figure S2c,d) in non-irradiated mice but also in
irradiated mice.
To summarize, hippocampal neurogenesis,
although not directly involved in the emergence of a
Figure 1 Focal hippocampal X-irradiation ablates cell proliferation in the subgranular zone (SGZ). (a) Schematic
representation of the experimental design. A first cohort of mice was used to assess SGZ cell proliferation, see (b) and (c).
Two other cohorts of mice were used for behavioral measures, see Figure 2. (b) Representative images of BrdUþ cells (‘black
cells’) in the SGZ (scale bar, 50mm). (c) The cell proliferation assessed by the number of BrdU-positive cells per mm
3 of the
granule cell layer (GCL), n=5–7 per group.
#P<0.05 UCMS mice vs control-vehicle mice; *P<0.05 and **P<0.01 UCMS-
fluoxetine mice vs UCMS-vehicle mice, or between line-connected groups. Data represent mean±s.e.m.
Figure 2 Hippocampal neurogenesis is required for the behavioral effects of fluoxetine but not of the corticotropin-releasing
factor 1 antagonist SSR125543. (a) Schematic representation of the apparatus used for the Cookie test (CT). (b, c) The
consumption of the cookie (number of bites) in the CT, n=13–14 per group for (b) and n=10 per group for (c).
#P<0.05 and
##P<0.01 UCMS mice vs control-vehicle mice; *P<0.05 and **P<0.01 UCMS-fluoxetine/SSR125543 mice vs UCMS-vehicle
mice. Data represent mean±s.e.m.
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was required for the recovery effects of the mono-
aminergic antidepressant fluoxetine. On the other
hand, alternative mechanisms, independent of neu-
rogenesis, may be used to induce similar effects by the
CRF1 antagonist, which directly target stress systems.
Chronic stress impairs hippocampal modulation of
brain areas involved in stress response
Our previous results raise the possibility that stimu-
lating neurogenesis by fluoxetine may facilitate the
regulation of stress systems. We therefore assessed
whether UCMS and fluoxetine affect the ability of the
hippocampus to modulate the downstream subcorti-
cal relay sites regulating PVN activity (Figure 3a). For
this purpose, mice were subjected to an intrahippo-
campal infusion with either the glucocorticoid recep-
tor agonist DEX (50ng) or vehicle (NaCl 0.9%, ethanol
0.2%) (Figures 3b and c). We then evaluated the
neuronal activation in the subcortical sites by im-
munodetection of Fos, product of an immediate
early gene (Figure 3d). As a control, Fos expression
was also quantified in the anteroventral BST, which
regulates PVN activity but is devoid of direct
hippocampal inputs. Intrahippocampal DEX
infusion in control-vehicle mice was able to
increase the number of Fos-labeled (Fosþ) cells in
several of these subcortical relay sites: lateral
septum (P=0.0043), amBST (P=0.0067), pmBST
(P=0.0014), medial preoptic area (P=0.0275), DMH
(P=0.0304) but not ventrolateral preoptic area
(P=0.124) and LH (P=0.174) (Figure 3e, Supplemen-
tary Figure S3). UCMS impaired the DEX-induced
increase of Fosþ cells in the latter regions, whereas
fluoxetine treatment counteracted the UCMS effects
except in DMH. No effect of UCMS or treatment was
found in the anteroventral BST (P=0.157). We then
tested if these effects can be reflected in the activation
of the PVN itself. Indeed, intrahippocampal DEX
infusion resulted in a significant increase of Fos
expression in the PVN of UCMS-vehicle but not
control-vehicle and UCMS-fluoxetine mice (P=0.0391).
In summary, UCMS exposure greatly lessened the
hippocampal regulation of the stress-integrative sub-
cortical sites, an effect mainly counteracted by
antidepressant treatment.
Chronic stress disrupts the sensitivity of the granule
cell network to novelty/glucocorticoid effects
We then directly tested the ability of the DG granule
neurons to react to glucocorticoids. These cells can be
activated and express immediate early genes when
individuals are exposed to a new environment.
48–50
We took advantage of this property to examine the
sensitivity of new and older granule cells to a new
environment exposure following a single injection
of DEX-P or vehicle (Figure 4a). For this purpose,
we concurrently labeled cells for the neuronal
marker NeuN, the immediate early gene product Fos
Figure 3 Chronic stress impairs hippocampal modulation of brain areas involved in the stress response, an effect reversed
by fluoxetine. (a) Schematic representation of the neurocircuitry underlying hippocampal regulation of the hypothalamo-
pituitary-adrenal (HPA) axis. Hippocampal CA1 and subiculum subregions send glutamatergic outputs (þ) toward
subcortical relay sites, such as medial preoptic area (mPOA) and ventrolateral preoptic area (vlPOA), anteromedial and
posteromedial bed nucleus of stria terminalis (amBST and pmBST), lateral septum (LS), dorsomedial and lateral
hypothalamic nuclei (DMH and LH). These sites contain GABAergic neuron population (–) underlying inhibitory influences
on the paraventricular nucleus (PVN). (b) Schematic representation of the experimental design. Veh and dexamethasone
(DEX) mean vehicle and DEX, respectively. (c) Schematic representation of the guide-cannula implantation (bar:
bregma= 3.08, lateral=±2.3, vertical= 1.4) and of the DEX infusion sites, one millimeter lower (asterisk). The figure is
adapted from Paxinos and Franklin (2001).
38 (d) Representative images of Fosþ cells from the amBST (scale bar, 50mm). (e)
Changes induced by intrahippocampal DEX infusion on the number of Fosþ cells in LS amBST, pmBST, mPOA, vlPOA,
DMH, LH, anteroventral BST (avBST) and PVN, n=4 per group.
#P<0.05 UCMS-vehicle mice vs control-vehicle mice;
wP<0.1 and *P<0.05 UCMS-fluoxetine mice vs UCMS-vehicle mice. Data represent mean±s.e.m.
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BrdU (4 week-old newborn cells) (Figure 4b).
We first assessed the effects on the whole granule
cell population (Figure 4c, P=0.0209). Although
UCMS-vehicle mice exhibited an apparent lower
NeuNþ/Fosþ cell density than the other mice, we
did not obtain any significant difference of neuronal
activation in response to novelty between the three
groups. On the other hand, a single DEX administra-
tion produced a trend to reduce the density of
NeuNþ/Fosþ cells in the GCL of the control mice
(B39%). Such a reduction was not found in UCMS-
vehicle mice (B11%), in contrast to UCMS-fluoxetine
mice (B35%).
We then focused on the newborn 4-week-old
neurons by assessing the density of NeuNþ/
BrdUþ/Fosþ cells in the GCL (Figure 4d,
P=0.0198). No effect of DEX was found in any group.
Although no difference appeared between control-
vehicle and UCMS-vehicle mice, fluoxetine signifi-
cantly increased the density of NeuNþ/BrdUþ/
Fosþ cells in UCMS mice. However, it cannot be
excluded that this effect reflects only the difference
in neurogenesis levels between UCMS-vehicle and
UCMS-fluoxetine (Supplementary Figure 1b). We
therefore aimed to validate the latter result by
calculating the rate of Fosþ in both NeuNþ cells
and NeuNþ/BrdUþ cells (Figure 4e, P=0.0226).
Again, fluoxetine significantly increased the rate of
NeuNþ/BrdUþ cells expressing Fos in UCMS mice
(2.26±0.62 in UCMS-fluoxetine vs 0.22±0.22 in
UCMS-vehicle) and even yielded to a trend for higher
proportions of Fosþ cells in young newborn neurons
(0.86±0.1 for NeuNþ cells), contrasting with both
control-vehicle and UCMS-vehicle mice.
However, the low frequency of Fos expression
throughout the GCL, along with the lower neurogen-
esis level in UCMS-vehicle mice, might prevent
reliable statistical comparisons by decreasing the
chance to meet triple labeling cells in these mice.
As a result, it is possible that differences between
UCMS-vehicle and UCMS-fluoxetine mice have been
artificially overstated (although it should also occur
with control mice, which was not the case). To obtain
data from a broader population of newborn neurons,
we analyzed the proportion of NeuNþ/Fosþ in the
inner part of the GCL containing the SGZ and high
proportion of young neurons (Figure 4b). This
Figure 4 Chronic stress and fluoxetine alters the sensitivity of newborn and older hippocampal granule cells to novelty/
glucocorticoid effects. (a) Schematic representation of the experimental design. (b) Representative images of NeuNþ (blue),
Fosþ (red), BrdUþ (green) cells and colocalization (merged) in the granular cell layer (GCL) of the dentate gyrus (scale bar,
50mm). Arrowheads show NeuNþ/BrdUþnewborn neurons. NeuNþ/Fosþ cells listed among cells belonging to the inner
part of the GCL (including the SGZ) are indicated by white arrows (NeuNþ/Fosþ/BrdU  cells) or arrowhead (NeuNþ/
Fosþ/BrdUþ cells). (c) The figure shows the effects of novelty and dexamethasone on the recruitment of granule cells
(NeuNþ/Fosþ cells per GCL mm
3), n=4–5 per group. The dark part at the basis of each bar represents the proportion of
NeuNþ/Fosþ cells listed in the inner part of the GCL. (d) The figure shows the effects of novelty and DEX on the
recruitment of newborn granule cells (NeuNþ/Fosþ/BrdUþ cells per GCL mm3), n=4–5 per group. (e) Proportion of Fosþ
cells (%) in NeuNþ/BrdU  cells and NeuNþ/BrdUþ cells of the GCL, n=8–10 per group. (f) Proportion of the NeuNþ/
Fosþ cells listed in the inner part of the GCL, n=8–10 per group.
#P<0.05 UCMS-vehicle mice vs control-vehicle mice;
*P<0.05 UCMS-fluoxetine mice vs UCMS-vehicle mice.
wP<0.1 Veh-treated mice vs DEX-treated mice or NeuNþ/BrdU 
cells vs NeuNþ/BrdUþ cells. DEX-P, dexamethasone-phosphate; Flx, fluoxetine; Veh, vehicle. Data represent mean±s.e.m.
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a greater proportion of Fosþ cells (B21%) than
control-vehicle (B15%) and UCMS-vehicle mice
(B16%) (Figures 4c–f; P=0.0186), confirming our
previous results with the BrdU labeling.
In summary, UCMS exposure decreased the sensi-
tivity of the GCL network to the combined novelty/
glucocorticoid effects. Fluoxetine was able to counter-
act this effect by recruiting higher proportions of
newborn granule cells.
Fluoxetine restores HPA axis negative feedback via a
neurogenesis-dependent mechanism
To examine more deeply the link between hippocam-
pal neurogenesis and stress response, we investigated
whether ablation of neurogenesis and UCMS induce
abnormalities in the HPA axis similar to those found
in anxiety/depressive disorders. A repeated collection
of fecal samples across 33h was performed on mice
previously exposed to a 7-week UCMS (Figure 5a and
b). Slight but significant effects of UCMS were
reported on the circadian activity of the HPA axis,
and fluoxetine partially reverse these effects in non-
irradiated mice (Supplementary Figure S4). We then
examined the integrity of the negative feedback
of the HPA axis through the DEX suppression test.
In this test, the administration of the glucocorticoid
receptor agonist DEX-P (0.1mgkg
 1, ip) is known to
suppress the subsequent release of endogenous
glucocorticoids in the plasma when negative feedback
integrity is undamaged. UCMS dampened the effec-
tiveness of the negative feedback (control B61% vs
UCMS B38%) whereas fluoxetine restored DEX-
induced suppression to control levels (B66%)
(Figure 5c, P=0.016). However, although ablation of
hippocampal neurogenesis did not significantly affect
the negative feedback integrity in control (B60%)
and UCMS (B30%) vehicle-treated mice, it signifi-
cantly attenuated the improvement of the HPA axis
negative feedback in UCMS mice by fluoxetine
treatment (B42%).
New neurons contribute to the hippocampal inhibition
of the stress response
Our latter results support the idea that neurogenesis
may subserve some stress integration roles of the
hippocampus. To precisely determine the role of the
new neurons on hippocampus-dependent regulation
of the stress response, we examined the ability of the
hippocampus to regulate HPA axis activity under
UCMS conditions and assessed how antidepressant
treatment and neurogenesis can affect this function.
Following UCMS exposure, mice were bilaterally
implanted with guide cannulas above the DG (Figures
6a and b) and injected with either DEX (50ng)
or vehicle (NaCl 0.9%, ethanol 0.2%). The results
demonstrated that the intrahippocampal DEX infu-
sion induced 51.2% plasmatic corticosterone sup-
pression in non-irradiated control mice (P=0.0034;
Figure 6c, Supplementary Figure S5). The neurogen-
esis ablation did not alter on its own the ability of the
hippocampus to inhibit the HPA axis, as suggested by
the 50.9% DEX-induced corticosterone suppression
in irradiated control mice. However, UCMS disrupted
hippocampal inhibition with low suppression in both
non-irradiated and irradiated mice (5.1 and 3.7%,
respectively). Finally, fluoxetine was able to restore
hippocampus-dependent negative feedback on the
HPA axis in non-irradiated UCMS mice to control
levels (56.1%), but not in irradiated UCMS mice
(12.4%). This latter result indicates that fluoxetine
requires new hippocampal neurons to re-establish the
hippocampal inhibition of the HPA axis under
chronic stress conditions.
Discussion
Since the first reports linking the behavioral effects of
antidepressants to hippocampal neurogenesis, there
has been little progress in understanding the specific
role of neurogenesis in antidepressant response.
Accordingly, it was necessary to identify hippocam-
pal functions that could be affected by adding
supplemental new neurons and then contribute to
Figure 5 Fluoxetine-induced improvement of the HPA axis negative feedback under chronic stress conditions involves
hippocampal neurogenesis. (a) Schematic representation of the experimental design. (b) Schedule of the fecal sample
collection and of the dexamethasone-phosphate (DEX-P) administration. (c) The DEX suppression test allowed assessing the
integrity of the HPA axis negative feedback. The figure shows the DEX-induced suppression of fecal corticosterone
metabolites (CORT), n=8–11 per group.
#P<0.05 UCMS-vehicle mice vs control-vehicle mice; *P<0.05 and **P<0.01
UCMS-fluoxetine mice vs UCMS-vehicle mice, or between line-connected groups. Data represent mean±s.e.m.
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sion-like states. We have identified such functions in
this study. Our findings reveal that chronic stress
exposure severely disrupts HPA axis activity,
hippocampal regulation of subcortical stress-integra-
tive structures, sensitivity of the granule cell network
to combined novelty/glucocorticoid effects and
hippocampus-dependent negative feedback of the
HPA axis. Furthermore, we demonstrate that the
SSRI fluoxetine uses neurogenesis-dependent me-
chanisms to restore hippocampal control over stress
systems as well as to reverse the behavioral and
physical effects of UCMS. Taken together, these
results provide direct evidence for a neurobiological
process through which neurogenesis participates to
antidepressant response: new neurons are recruited
by antidepressant drugs to reestablish hippocampal
regulation of stress systems, which in turn could
initiate recovery.
There has been much discussion about a possible
causative role for adult neurogenesis in anxiety/
depression.
51–54 Our results do not support such a
possibility. First, in line with previous studies, the
ablation of adult-generated hippocampal neurons
does not cause any anxiety/depression-like states
(but see ref. 7),
3,12–15,55–58 or increases vulnerability
to chronic stress.
11 Second, enhancing neurogenesis is
unlikely to be the final process through which
recovery becomes possible. Indeed, although we
confirmed that hippocampal neurogenesis is required
for the reversal of the behavioral and physical effects
of UCMS by monoaminergic antidepressants (fluox-
etine and imipramine),
11 we also established that a
similar reversal can be elicited even in animals with
ablated neurogenesis by compounds targeting directly
stress response circuits (CRF1 or vasopressin 1b
antagonists).
11 As a consequence, elevations of hip-
pocampal neurogenesis may be a crucial but indirect
pathway through which monoaminergic antidepres-
sants exert effects on downstream structures and then
underlie recovery.
We previously showed that fluoxetine required
hippocampal neurogenesis to reverse UCMS effects
in standard behavioral tests, such as the Novelty-
Suppressed Feeding (NSF) test.
11 It is noteworthy that
we extend here such results to alterations more
relevant for depressive disorders, such as anhedonia
or body weight changes.
59 This is critical as it has
recently been shown that not all tests sensitive to the
behavioral effects of antidepressants might involve
neurogenesis-dependent mechanisms.
15 Moreover,
the neurogenesis-dependence seems to emerge only
under chronic stress or corticosterone treatment for
mouse strains such as C57BL/6 or BALB/c.
11,15 In
contrast to chronically stressed mice,
11,37 fluoxetine
may induce some behavioral effects independent of
neurogenesis and fail to alter neurogenesis in un-
stressed BALB/c mice.
58,60 Considering that antide-
pressants are mainly devoid of mood-changing effects
in non-depressed healthy humans
61–63 and that
fluoxetine effects on behavior and large-scale gene
expression greatly differ depending if the mice are
under control or UCMS conditions,
33 paradigms
elaborated in ‘non-depressed’ mice may engage differ-
ent neurobiological mechanisms that are perhaps
irrelevant to clinical remission. Rather, it is likely that
relevant antidepressant effects are conditional on the
presence of a disorder-related neuropathology.
36 In the
same vein, antidepressant effects that arise during
treatment shorter than 14 days are obviously assumed
to be neurogenesis-independent.
56,58,64 Indeed, antide-
pressants require more than 1 week to significantly
increase SGZ cell proliferation
3,4 and it takes 1–2
weeks for new cells to start to integrate into the
network.
65 This timeframe suggests that at least 2–3
weeks should be expected before the neurogenic effects
of antidepressants can significantly impact the DG
network if so. It is noteworthy that this delay parallels
Figure 6 Adult-generated granule neurons are required to restore the hippocampal inhibition of the hypothalamo-pituitary-
adrenal axis under chronic stress conditions. (a) Schematic representation of the experimental design. (b) Schematic
representation of the guide-cannula implantation (bar: bregma= 3.08, lateral=±2.3, vertical= 1.4) and of the
dexamethasone (DEX) infusion sites, one millimeter lower (asterisk). The figure is adapted from Paxinos and Franklin
(2001).
38 (c) An intrahippocampal DEX suppression test has been used to test the ability of hippocampus to inhibit the HPA
axis. The figure shows the corticosterone (CORT) suppression induced by intrahippocampal DEX infusion, n=7–8 per group.
#P<0.05 UCMS mice vs control-vehicle mice; *P<0.05 and **P<0.01 UCMS-fluoxetine mice vs UCMS-vehicle mice, or
between line-connected groups. Veh, vehicle; DEX, dexamethasone. Data represent mean±s.e.m.
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fluoxetine in the UCMS model.
11,33,45 This temporal
correlation strengthens the idea that neurogenesis
may be required for fluoxetine to reverse UCMS-
induced effects. Interestingly, this timeframe also
parallels the delay before the first beneficial effects
in patients with major depression,
66 suggesting that
neurogenesis could also be involved in antidepres-
sant effects in humans. The two first studies investi-
gating the relationship between hippocampal
neurogenesis and antidepressant drugs in depressed
patients have yielded mixed results: an increase of the
SGZ neural progenitors was found after antidepres-
sant treatment in adult, but not elderly patients.
5,6
One meaningful finding of our study is that,
without hippocampal neurogenesis, fluoxetine be-
comes unable to restore under chronic stress condi-
tions the hippocampus-dependent inhibition of the
HPA axis as well as to reverse the behavioral and
physical alterations. This suggests that the improve-
ment of stress system regulation is a critical process in
the therapeutic action of antidepressants, at least in
the substantial subset of patients with altered HPA
axis reactivity. This is consistent with clinical data
which demonstrate that, in most patients with altered
HPA axis negative feedback, remission and decreased
risk of relapse are associated with the improvement
of HPA axis functioning.
28–31 Overall, this finding
reveals that the hippocampus not only regulates brain
systems involved in the stress response at baseline but is
also critical in mediating the ability of monoaminergic
antidepressants to modulate stress response, probably
through newly generated neurons. This possibility is
in agreement with a brief report indicating that
neurogenesis inhibition may yield higher corticoster-
one secretion in mice following exposure to a new
bright-light condition, suggesting that even under
conditions when the negative feedback is not fully
desensitized, newborn neurons may have a more
subtle role in dampening the response to stress.
67
As a consequence, we aimed to scrutinize precisely
the relationships between the hippocampus and
stress response systems. Specifically a single pre-
administration of the synthetic glucocorticoid DEX
decreased Fos expression in the GCL of control-
vehicle mice exposed to a new context. These
differences in granule cell activation could poten-
tially influence the activity of the next hippocampal
cell layer (CA3)
68 and then enable the hippocampal
network to couple stress and contextual informa-
tion.
69 Hence, a possible interpretation is to consider
this reduction as a manner for the granule cell
population to take into account, at the network level,
glucocorticoid releases during new contextual inputs.
On the other hand, this Fos-induction produced by
novelty is disrupted under chronic stress with no
additional effect of exogenous glucocorticoids. It is
therefore conceivable that the alteration of the GCL
sensitivity leads to disturbances in information
processing and stress integration. We tested this
possibility by probing the neurocircuitry connecting
the hippocampus to the HPA axis.
21,22 Our results
demonstrate that chronic stress profoundly moderates
the hippocampal influence on subcortical structures
involved in the stress response such as lateral septum,
BST, preoptic area and DMH. Taken together, these
results suggest that chronic stress, by decreasing
inhibitory regulation from the hippocampus, may bias
the net input balance toward greater excitatory influ-
ences into the PVN leading to its overactivation and
perhaps underlying the impairments of the hippocam-
pus-dependent negative feedback on the HPA axis.
Strikingly, the Fos induction in the GCL and the
response to exogenous glucocorticoids are preserved
in fluoxetine-treated UCMS mice. Antidepressant
treatment is therefore able to restore under chronic
stress conditions the sensitivity of the granule cell
network to novelty/glucocorticoid effects. As adult-
generated granule cells are continuously added to the
network, they are a potential source of new sensitive
neurons with enhanced plasticity and excitabil-
ity.
57,70–74 Considering that fluoxetine treatment in-
creased neurogenesis levels in UCMS mice, it was
then conceivable that such compounds compensate
the chronic stress effects on GCL network activity by
recruiting higher proportions of adult newborn
neurons among the granule cells expressing Fos.
Indeed, this hypothesis was confirmed in UCMS-
fluoxetine mice with a greater density of 4-week-old
newborn cells expressing Fos and a higher rate of
Fosþneurons in the inner GCL (containing high
levels of newborn young neurons).
41–44 Enhancing
neurogenesis may thus be a way for antidepressant
drugs to add a fresh source of new sensitive neurons
that may affect hippocampal functioning and then
improve stress integration.
Interestingly, the proportion of Fos expression in
the inner GCL of UCMS-fluoxetine mice are even
greater than in control-vehicle mice, which also
exhibited high levels of SGZ cell proliferation and
neurogenesis. A potential explanation is that fluox-
etine does not only enhance neurogenesis but also
accelerates maturation and synaptic integration of the
newborn neurons, as already shown.
14 This effect may
promote their recruitment and thus contribute to
counteract the effects induced by chronic stress. As a
matter of fact, the higher proportion of Fos expression
in the BrdUþ cells, which was found exclusively in
UCMS-fluoxetine mice appears to strengthen this
interpretation. Another important question is whether
or not the effects of newborn neurons during such
processes are direct. The fact that Fos expression has
been found in BrdUþ cells supports this idea.
Moreover, newborn granule cells in mice can begin
to express glucocorticoid receptor early: 66% 1 week
after BrdU integration and almost 100% four weeks
after BrdU integration (as high as older mature
neurons).
75 These data suggest that newborn neurons
may potentially be sensitive to glucocorticoid release
during their development. However, we did not
report any significant change induced by DEX
indicating that newborn neurons could actually be
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These results are surprising because taken together
they indicate that the reduction of the GCL network
activation induced by DEX can paradoxically be
improved by increasing a population of young neurons
though less sensitive to DEX. This apparent discre-
pancy can be enlightened by a recent study,
76 where the
authors demonstrated that a limited amount of new-
born granule cells is able to negatively modulate the
activity in the larger population of mature granule cells,
maybe by preferentially activating inhibitory interneur-
ons. Accordingly, it is conceivable that, in our context,
DEX biases the balance of activity toward young
granule cells (if less sensitive to DEX), then potentiat-
ing the DEX-induced reduction of the activation of
older granule cells. Within this framework, fluoxetine,
by enhancing neurogenesis and perhaps improving
maturation, might re-establish the sensitivity of the
GCL network to novelty/glucocorticoid effects.
The hippocampus is also highly interconnected
with various corticolimbic structures, which control
the stress response, emotion and motivation such as
the amygdala, cingulate gyrus, prefrontal cortex and
ventral striatum.
16–18 These structures are thought
to be involved in an integrated stress response and
underlie the main pathological manifestations of
anxiety/depressive disorders.
77–79 It is therefore con-
ceivable that the UCMS-induced HPA axis abnormal-
ities represent only a measurable fraction of larger
changes in the stress integration system and that
elevation of hippocampal neurogenesis might enable
monoaminergic antidepressants to strengthen hippo-
campal influences on these brain regions.
Another important finding of our study is that
inhibition of hippocampal neurogenesis does not
cause any alteration of the HPA axis functioning or
regulation in both control- and UCMS-vehicle mice.
The hippocampus is known to contribute to HPA axis
regulation: its stimulation can reduce glucocorticoid
secretion
80,81 whereas hippocampal damages can
increase stress-induced glucocorticoid release.
82,83 In
spite of this, none of our previous and current results
suggest that neurogenesis disruption alone substan-
tially disrupts either the circadian rhythm of HPA axis
activity or the stress response.
3 Defects in hippocam-
pal functioning should therefore require larger altera-
tions in the intrinsic biology of the hippocampus than
a neurogenesis decline alone. Accordingly, these
results reveal that neurogenesis may not be the driver
of the hippocampal regulation on the HPA axis, at
least without greater environmental challenges.
Taken together, our data suggest that, while hippo-
campal neurogenesis would contribute to the im-
provement of stress integration by antidepressants
during chronic stress exposure, its role could be less
important in the absence of previous deficiencies
or pathological situations. This result parallels
the Kempermann’s hypothesis of the neurogenic
reserve.
84 He suggests that adult newborn hippocam-
pal neurons would constitute a reserve, inessential in
normal conditions, but which could become decisive
when the organism is confronted with novelty or
complex situations. In our context, new hippocampal
neurons might thus be critical for antidepressant
effects only when the hippocampus-dependent reg-
ulation of the stress system is deficient.
In conclusion, this study demonstrates how hippo-
campal neurogenesis can contribute to regulate the
stress hormone system. This function may explain
why adult-generated granule cells are required for
several behavioral effects of monoaminergic anti-
depressants. However, not all the patients with
anxiety/depression display HPA axis abnormalities,
85
as well as not all the mouse strains exhibit HPA axis
disturbances following UCMS exposure.
45 It is there-
fore likely that the extent of neurogenesis involve-
ment in antidepressant effects can depend on the
degree of stress system alterations for each subject or
mouse strain. Interestingly, the previous conflicting
results can be enlightened by this hypothesis. Indeed,
the utilization of control non-stressed mice or
stressed mice without any significant alterations of
stress systems would be less appropriate to highlight
the role of adult-generated hippocampal neurons in
antidepressant effects.
56,58 In the same vein, not all the
patients respond to antidepressant therapies; accord-
ingly, extending this work to the mechanisms of what
is happening in anxious/depressed patients might be
limited to some subtypes of stress-related disorders or
subgroups of patients. Future studies will therefore
have to examine whether stress system alterations are
clearly a condition for the neurogenesis involvement
in antidepressant effects and whether adult-generated
hippocampal neurons can influence stress integration
in other relevant brain regions such as the prefrontal
cortex, cingulate cortex or amygdala.
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